SOURCE: MYOS Corporation

MYOS Corporation

January 07, 2015 07:05 ET

MYOS Corporation to Present at the Eighth Annual OneMedForum Conference on January 13, 2015

Presentation and Live Webcast on Tuesday, January 13, 2015, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time

CEDAR KNOLLS, NJ--(Marketwired - Jan 7, 2015) - MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that its Chief Medical Officer, Robert Ashton, M.D., will be presenting a corporate update at the Eighth Annual OneMedForum conference being held January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA.

Event: OneMedForum Presentation
Date: Tuesday, January 13, 2015
Time: 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time
Location: Marriott Marquis, San Francisco, CA

A live audio webcast of the presentation will be available on the Company's website at www.myoscorp.com in the Investor Relations section (http://ir.myoscorp.com/) on the Upcoming Events page on the IR Calendar at http://ir.myoscorp.com/ir-calendar. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About OneMedForum
OneMedForum was launched in 2008 to bring together the companies and investors that OneMedPlace was beginning to cultivate through its online community. The date and location were selected to leverage the influx of healthcare investors and company executives that gather each January in San Francisco. OneMed has continuously worked to facilitate the discovery of lesser-known quality companies, with a range of media tools, technologies, and content that have been developed over the past eight years. Since 2008, over 400 companies have presented at OneMedForum, and almost 300 leading investors have served on panels.

About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company," visit www.myoscorp.com.

The Company's first commercial product containing Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our products, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to successfully develop and launch our own core branded products, the ability to collect our accounts receivable from our distributors, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to enter into strategic relationships with new distributors, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Contact Information

  • MYOS Corporation Investor and Media Contact:

    Jenene Thomas
    Investor Relations and Corporate Communications
    (973) 509-0444
    Email Contact